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Abstract
Author Manuscript

Obesity is a major global epidemic that sets the stage for diverse multiple pathologies, including
cardiovascular disease. The obesity-related low grade chronic inflamed milieu is more pronounced
in aging and responsive to cardiac dysfunction in heart failure pathology. Metabolic dysregulation
of obesity integrates with immune reservoir in spleen and kidney network. Therefore, an
integrative systems biology approach is necessary to delay progressive cardiac alternations. The
purpose of this comprehensive review is to largely discuss the impact of obesity on the
cardiovascular pathobiology in the context of problems and challenges, with major emphasis on
the diversified models, and to study cardiac remodeling in obesity. The information in this article
is immensely helpful in teaching advanced undergraduate, graduate, and medical students about
the advancement and impact of obesity on cardiovascular health.
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Introduction
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In recent years, it is evident that a sedentary lifestyle an unhealthy diet enriched with
processed and preserved foods, and lack of sleep and exercise have led to an obesity
epidemic. The individuals who possess a body mass index (BMI) of 30 or greater are
considered obese and overweight. The trend for the obesity population in the United States
is tracked by national survey data, which includes the measured heights and weights of
participants to calculate BMI. Data from the National Health and Nutrition Examination
Survey revealed that the prevalence of obesity among adults in the United States is > 35.5%
for men and women(46). It is widely accepted that obesity increases the risk of heart disease,
although there is evidence that some obese patients have survival benefits once diagnosed
with cardiovascular disease, which begs the question of whether there is a “healthy” obesity.
A recent meta-analysis on this subject appears to have demystified this idea. It identified
61,836 individuals from 8 different studies to investigate the associations of BMI and
metabolic status with total mortality and cardiovascular events (61). The study highlights
that metabolically healthy non-obese individuals have lower risk of total mortality and
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cardiovascular events than the metabolically healthy obese group. This increased risk in
obese but metabolically healthy people was only observed in studies with 10 or more years
of follow-up, suggesting a possible explanation for the façade of "healthy" obesity (35, 92).
Primarily, obesity is marked by chronic low-grade inflammation that is responsible for the
genesis of many diseases, including insulin resistance, type 2 diabetes, metabolic syndrome,
atherosclerosis and hyperlipidemia (68) (70). The cluster of these metabolic abnormalities
makes individuals prone to the incidence of myocardial infarction (MI) events and
subsequent heart failure pathology.

Nutrition, inflammation and cardiovascular disease
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The fatty acid composition of leukocytes, other immune cells, and non-immune cells
changed according to the intake of fatty acid(s) in the diet. The essential and conditional
fatty acids play an immunomodulatory role, which is useful for the management of chronic
inflammation processes, such as autoimmune diseases (lupus) (32). Traditionally, specific
immune cell-derived cytokines or percentage population of a specific cell population is
prominent markers of inflammation in obesity and cardiovascular disease. Undernutrition or
over-nutrition is the driving force that alters the immune system network in heart failure
pathology, particularly in aging (52). At this point, due to obesity-related changes in
microenvironment, it is unclear whether these cytokines are causes or end stage
consequences of the disease process (Figure 1). It was well-established in the 18–19th
century that acute inflammation is host-protective, self-healing, and characterized by five
cardinal signs: rubor (redness), calor (increased heat), tumor (swelling), dolor (pain), and
functio laesa (loss of function) (96). The first four were described by Celsus in the
eighteenth century, and the fifth was added by Virchow in the nineteenth century (115).
Edema or swollen limbs are the main signs of chronic inflammation in advanced heart
failure patients and are often accompanied by fatigue and pulmonary congestion (94). Of
note, the edematous milieu in response to acute inflammatory response is essential, but the
triggers that develop chronic heart failure setting are unknown.

Failure and success of pharmacological versus nutritional approaches
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Cyclooxygenase (COX)-2 is a lipid/fatty acid metabolizing enzyme also known as
prostaglandin-endoperoxide synthase, and its inhibition is attempted to develop safe nonsteroidal inflammatory drugs. However, use of COX-2 inhibition is associated with a series
of cardiovascular adverse effects, including the development of stroke, atrial fibrillation, and
MI events (64) (95). COX-2 uses arachidonic acid as the fatty acid substrate and is
responsible for the generation of prostaglandins, prostanoids, prostacyclins, and
thromboxane. Failure of COX-2 inhibitors (e.g. rofecoxib and valdecoxib) after FDA
approval indicates the complexity of nutrition and lipid metabolism machinery in
cardiovascular disease pathology. Likewise, single and specific cytokine hypothesis resulted
in disappointing results in acute and chronic heart failure trials (36). Pre-clinical studies
showed that treatment or overexpression of TNF-α leads to aggravation of HF, and
inhibition of TNF-α recovers left ventricle function in heart failure pathology (18, 37).
However, the overall results in clinical trials were harmful to heart failure patients. A
comprehensive summary of RENWAL, RENIASSANCE and RECOVER trials suggest that

Compr Physiol. Author manuscript; available in PMC 2018 September 12.

Halade and Kain

Page 3

Author Manuscript
Author Manuscript

use of TNF-α inhibitors is a deceptive strategy to control inflammation in chronic heart
failure patients. Thus, it is necessary to delineate the physiological, adaptive and
pathological role of TNF-α in response to MI. In relation to the failure of pharmacological
strategies, it is also important to consider the nutritional and dietary approach to prevent and
treat cardiovascular diseases such as heart failure. In particular, omega-3 fatty acids intake is
cardioprotective, though the mechanism of action is unclear. The number of reports from
preclinical and clinical studies, as well as the epidemiological studies, suggested that the
supplementation of dietary omega-3 fatty acids could be beneficial for heart failure patients
(87). The double blind and randomized GISSI-HF trial showed that long-term
supplementation of fish oil (1g) to heart failure patients reduced endpoints of all-causes
mortality and readmission for cardiovascular complications (108). The Recent PREDIMED
study supports the GISSI-HF outcome that reveals prior cardiovascular disease, relatively
higher fish intake, and dietary alpha linoleic acid (one of the omega-3 fatty acid) sourced
from walnuts and olive oil limit all-causes mortality, but the protection from cardiac death
comes only from fish-derived long-chain omega-3 fatty acids (101). Nineteen countries
comprehensive studies of free-living populations suggest that concentrations of seafood and
plant-derived ω-3 fatty acids biomarkers are associated with a modestly lower incidence of
fatal CHD (33). With examples of omega-3 fatty acids in the prevention of cardiovascular
disease, dietary approaches outweigh pharmacological approaches in effectiveness.

Distinct challenges in cardiovascular world

Author Manuscript

In addition to the advancement of technology, mortality-related cardiovascular disease is a
prominent challenge to developed and developing nations. Sedentary lifestyle and
prevalence of processed food intake alter the body’s metabolic parameters, including
increased number of acute coronary syndrome events (4) (90). In response to acute coronary
syndrome or MI, the left ventricle experiences dilative changes in size, shape, and function.
Though post-MI, overall patient’s survival increased the total mortality also increased within
five years due to heart failure progression and pathological remodeling. Traditionally, the
number of drugs and dietary intervention are tested with primary focus on inflammation
relevant to prevention strategy, but with limited focus on integrative approach. For
simplification, cardiovascular disease challenges are divided into the following four
categories (94).

Author Manuscript

1.

MI-prone subjects – obesity, diabetes, hypertension and aging

2.

Post-MI morbid patients – 2–17% die within year (non-resolving patients)

3.

Less morbid patients but prone to death - >45% patients die with-in five years
post- MI

4.

Advanced chronic heart failure patients alive after five years but with limited
mobility and high discomfort

Integrative approach for heart failure management
Aging is an inevitable and inherent factor, and coupled with obesity, diabetes, hypertension
and other metabolic disorders, it leads to the progressive development of cardiac dysfunction
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and failure (80, 112). Heart-failure free survival is feasible for a period of 3 to 15 years in
the absence of metabolic syndromes (2). MI-induced pathological remodeling not only
damages myocardium, but also impacts kidney and spleen network to control physiological
homeostatic mechanism (52). Therefore, comprehensive and systemic biology integrative
approaches are necessary for the prevention and treatment of cardiovascular disease.
Application of diversified ‘omics’ approaches such as proteomics, metabolomics and
lipidomics allow for understanding of the chemical milieu that facilitates intra-intercellular
chemical communication (28, 29, 53, 71). Specifically, circulating leukocytes and immune
cells are sensitive to surrounding microenvironment in order to promote physiological or
pathological function. Immune cells express a broad range of ligands that are vulnerable to
disease pathology acts in coordination with the nervous system as sixth sense in response to
stimuli like infection or myocardial damage (15). One hypothesis is that after MI, overactive
inflammation is one possible cause of heart failure; likewise a variety of chronic
inflammatory disease such autoimmune disease lupus, asthmas, and allergies share frustrated
resolution (36, 49). Recent microbiome studies emphasized the importance of nutrient
bacterial metabolites to sensitize or desensitize immune cells (111). Nutrition is one of the
prime critical factors for atherogenesis, atheroprogression, and atherosclerosis, and
atherosclerosis forms fatty streaks in the coronary vessel due to unresolved or un-cleared
inflammation (111, 117). Immune cells (e.g. monocytes and macrophages) are exclusive
defensive cells that respond to action (exercise) and inaction, the sleep and awake cycle, and
overnutrition and undernutrition to maintain homeostatic cardiac physiology (67, 88).
Imbalance of these three pairs leads to progressive changes in immune system response to
cardiac damage repair. Traditionally, in obesity research, the low-grade inflammation is
much more focused rather than overnutrition or undernutrition; however, the global and
systems biology integrative approaches are essential for a possible method for the prevention
of heart failure and long-term, heart-failure-free survival.

Obesity prevalence and the cardiovascular outcome

Author Manuscript

The World Health Organization defines overweight and obese as having an abnormal or
excessive fat accumulation that poses a risk to cardiovascular disease and all-causes
mortality (90). The body mass index (BMI), a person’s weight (in kilograms) divided by the
square of his or her height (in meters), is well-accepted as the traditional measure of obesity.
A person with a BMI of 20–25 kg/m2 is considered healthy, and above 25 kg/m2 is
considered overweight. Furthermore, obesity is subdivided into three classes according to
BMI: of Class I (30–35 kg/m2), Class II (35–40 kg/m2) and Class III (<40 kg/m2). Recently,
a new method was identified to quantify the risk specifically associated with abdominal
obesity, known as A Body Shape Index (ABSI). ABSI is based on waist circumference and
is adjusted for height and weight: ABSI ≡ WC / (BMI (2/3) x height(1/2)). ABSI is claimed
to be a more effective predictor of mortality than BMI, the most common measure used to
define obesity (74). Obesity facilitates low-grade chronic inflammation that leads to the
development of metabolic syndrome. Being overweight or obesity increases in the general
population the risk of atherogenesis, MI and subsequent chronic heart failure with or without
metabolic syndrome (110).
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Diet-induced obesity, nutrition and left ventricle function
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A classical study compared milk and lard fat to determine if a high fat diet was sufficient to
cause cardiac dysfunction in mice (19). There were 3 distinct approaches used to evaluate
the effect of obesity on left ventricle. The first aspect was subjecting mice to two different
high fat diets, lard or milk, and following them over a period of 6 months. The second point
involved high-fat feeding during or before and during heart failure. The final part of the
study included a commonly used mouse model of overt diabetes, hyperglycemia, and obesity
(db/db mice) being subjected to pressure overload and ischemia-reperfusion. In all aspects of
the study, cardiac dysfunction was determined by echocardiographic measurements. In the
first part, researchers showed that mice on the lard diet exhibited higher fractional
shortening compared to low-fat diet and milk, but this difference was attributed to a
reduction in systolic diameter in the lard diet group compared to the low-fat group. This
study concludes that chronic fat feeding (6 months) is inadequate to develop left ventricle
dilation or cardiac dysfunction. In the second part, there was no significance difference
observed in the mortality in the mice that were fed a high-fat diet before ligation inducedinfarction and mice that were not on a high-fat diet. Both groups had significant changes
post-MI, but no difference was observed in LV end systolic and diastolic pressures between
the high fat and standard diet groups. These findings led the researchers to make the
conclusion that exposure to a high-fat diet does not alter the progression of heart failure in
mice. This claim was further supported by the observation that there are no differences in
mitochondrial function between the groups. The results of the second aspect of the study led
the researchers into their final part of the study, investigating the effects of hyperglycemia
and obesity on heart failure progression. Using the db/db mice model and their heterozygous
littermates as two cohorts, the mice were subjected to permanent coronary ligation,
myocardial ischemia/reperfusion or transverse aortic constriction (TAC). Only the TAC
portion was continued after significant mortalities were encountered using other methods.
The results found a baseline difference in ejection fractions and end systolic volumes
between groups, but not ECG differences between the groups following TAC. These results
led researchers to test if cardiac dysfunction during TAC can be attributed to
hypoinsulinemia. This was tested by injecting mice with streptozotocin and subjecting them
to TAC with cardiac function being assessed via ECG. The results showed no changes in the
ejection fractions and fractional shortening between the groups throughout 8 weeks of TAC.
The first conclusion drawn from these results was that increased fat intake, either before or
after MI, does not exacerbate cardiac dysfunction. The second was that severe
hyperglycemia or hypoinsulinemia does not cause any significant adverse effects during
pressure overload-induced heart failure. The results also suggest the possibility that a high
fat diet confers no greater risk to cardiac function once heart failure has been induced by
surgical infarct. The researchers are poised in their conclusion that high-fat diet alone may
not be sufficient to produce systolic dysfunction in mice, since mice exposed to the high-fat
diet before or after infarct-induced heart failure show no exacerbation of cardiac
dysfunction. Mice with hyperglycemia or hypoinsulinemia also exhibited no change in
cardiac dysfunction. Presented findings and their conclusions raise the notion that certain
mouse models may fail to recapture complex physiology and lipid metabolism of humans
because feeding rodents on a high-fat diet could be merely copying the phenotype in humans
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consuming a Western diet. Future studies could involve including a high-fat diet combined
with a high sucrose diet to accurately mimic a human diet, and also could explore the
contribution of potential environmental factors to high-fat-diet-induced cardiac dysfunction
that had been previously reported (19).
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In recent years, obesity has become a reason for concern and reported to be associated with
type II diabetes mellitus, metabolic disorders, hypertension and cardiovascular disease (106,
107, 113). The studies have revealed obesity as one of the relevant comorbidities of patients
with ischemic heart disease leading to increase in mortality and development of congestive
heart failure after MI. Using the murine model of diet-induced obesity, Thakkar et al have
investigated the impact of diet-induced obesity after myocardial ischemia-reperfusion injury
in mice (109). In mice, diet-induced obesity (DIO) develops hyperinsulinemia and insulin
resistance and hepatic steatosis, with significant ectopic lipid deposition in the heart with
cardiac hypertrophy and non-significant changes in blood pressure. The DIO mice showed
the altered cytokines profile with increase in proinflammatory markers. The obese mice
showed hypertrophic remodeling to MI with reperfusion and increase in LV chamber size in
infarcted hearts compared with lean mice. The study is supported by Lopez et al., where
excess n-6 fatty acid-induced obesity developed early post-MI LV dysfunction, impaired
resolution of inflammation, and delayed LV healing in aging, along with dysregulation of
proinflammatory analytes such as a 12-hydroxyeicosatetraenoic acid (12-S-HETE) (80). In a
recent study, Halade and colleagues showed that the excess intake of fatty acid is deleterious
in aging, leading to adverse MI-remodeling. Quantitative analysis of fat metabolites using
mass spectrometry in young vs. aging mice displayed higher levels of arachidonic acid (AA)
and minimal formation of pro-resolving, D- and E- series resolvins in aging mice fed with
excess n-6 diet. The excess n-6 feeding in aging mice also displayed higher proinflammatory (CD11b+F4/80+Ly6Chi) immune population (Figure 2). The study highlighted
the systems biology approach and focused on the cardiorenal axis. The study showed
dysregulation of metabolites and cytokines not only in heart, but the n-6 fatty acid feeding
also induced renal inflammation impacting kidney, with increase in NGAL, TNF-α and
IL-1β (52). In contrast, the study by Poncelas et al., where B6D2F1 mice of both genders
when fed on the high-fat diet (HFD) or standard diet for six months and then subjected to 45
min of coronary occlusion and 28 days of reperfusion, mice developed obesity with
hypercholesterolemia and hyperinsulinemia in the absence of hyperglycemia or hypertension
(93), though no change was observed in ventricular mass, volume or function, or in vascular
reactivity during feeding. HFD showed the reduction in infarct size and cardiac dilation, as
well as improved left ventricular function as compared to control diet animals attenuating
the consequences of transient coronary occlusion as shown by a marker. A study by
Heaberlin et al. in KKAy mouse model of obesity and type 2 diabetes showed improved
cardiac function through reduced inflammation, extracellular matrix accumulation, and
neovascularization in the infarct region with decreasing survival post-MI. KKAy mice
showed increased post-MI mortality, while survivors had improved cardiac function
accompanied by reduced macrophages, collagen I and III, and neovascularization (60).
Considering the human, in a meta-analysis study with a sample size of 36,803 participants,
there were 14,883 incident cases of MI event. This showed that both overweight and obesity
increased the risk of AMI (126). Obesity is considered to be an independent risk factor for
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MI analyzed, using data from a case study (104). Human studies have shown that the obesity
is considered to be a metabolic syndrome which doubles the cardiovascular outcomes and
mortality (86). Being overweight and obese independently increased the risk of heart disease
in patients with type 2 diabetes. However, the paradoxical studies are also published with
mice and human data. The long-term mortality was lower in the patients that were obese and
older after non-ST-segment-elevation MI compared to those of with healthy weight (89).
Though the obesity paradox is found in both mice and human studies, has been observed
that age and gender both are the crucial factors in determining the outcomes of obesityinduced cardiovascular risk factors.
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Obesity is associated with the shift in structural and functional parameters of the heart, such
as LV hypertrophy, left atrial enlargement and impairment of LV systolic/diastolic function.
It is thought that long-term obesity leads to an exacerbation of heart failure, but there are no
firm conclusions on the particular role obesity plays in the development of heart failure (1).
Previous studies have shown that obesity is a major contributor to cardiac complications and
all-causes mortality, independently of association with other cardiovascular risk factors.
Obesity is characterized by bone and liver adiposity, and excessive chronic inflammation of
adipose tissue with marked molecular and cellular dysregulation in various organs (Figure 3)
(51, 55, 56). The high metabolic requirements of the excess adipose tissue cause larger
amount of cardiac work, resulting in an increase in LV mass. Obesity-mediated cardiac
remodeling is characterized by a shift to a concentric geometry. Obese individual’s heart
exhibits many differences from the normal heart; epicardial fat is thicker and the left atrium
increases in size (8). The left ventricle of obese individuals shows normal ejection fractions,
increased stroke volume, and reduced strain, mid wall shortening, and filling rate. The LV
structure also shows an increase in relative wall thickness (8). Thus, obesity increases the
risks due to the structural and functional cardiac changes coupled with a prevalence to
develop coexisting conditions that also contribute to cardiac dysfunction. Obesity impacts on
the structure and function of the heart and the obvious connection between nutrition and
obesity. The role of nutrition in LV function and CVD is of fundamental interest. Recent
studies were performed in rodents to assess the role of diet in the progression of heart
failure. Dietary lipids were presumed as the membrane phospholipids; now it is clear that
these lipidic molecules coordinate signaling event and acts as ligands for nuclear receptors
(105). Recent studies performed in rodents suggested that high-fat diet and low in
carbohydrate prevents development and progression of heart failure when compared to low
fat and high carbohydrate diets (105). There is need of two sets of dietary recommendations,
one for individuals who are at risk for heart failure and another one for those who have
established heart failure.
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Fatty acids signaling in myocardium metabolic remodeling
In a study of the Burmese python as a model of acute cardiac metabolic regulation, there
was an indication of an increase in heart mass after consuming a meal. Most of the
mammalian models typically show modest hypertrophy (~10 to 20%) after weeks of
stimulation; however, the python heart shows a massive hypertrophy as it grows by 40%
with 48 to 72 hours after the consumption of a large meal. The increase in heart mass is
regulated by the increase in AMPK, AKT, GSK3 β and mTOR phosphorylation in the
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postprandial python heart. At the same time, the plasma non-esterified fatty acids and
triglycerides are significantly increased after an enormous meal without an accumulation of
neutral lipids. Treatment of neonatal rat ventricular myocytes with postprandial plasma from
fed python significantly increased their cell size, indicating the role of circulating fatty acids
in hypertrophy. The complex mixture of the fatty acids is myristic acid (C14:0), palmitic
acid (16:0), and (C16:1). Palmitoleic acid feeding to the python also results in an increase of
heart mass. Even with the well-established pro-apoptotic action of the palmitic acid in
cardiomyocytes, there is no evidence of this in the python plasma treated myocytes.
Interestingly, the infusion of the complex fatty acid mixture into the python for seven days
causes the development of cardiac hypertrophy with no activation of fetal genes or signs of
fibrosis. This overall data suggests the beneficial role of fatty acids in heart growth
characterized by cellular hypertrophy in the absence of hyperplasia.(99)
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Effects of obesity on ECGs (electrocardiogram) in humans and mice
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Obesity in humans is associated with long QT in electrocardiogram (ECG) measurements,
an increase in the frequency of premature ventricular complex and sudden cardiac death. A
study was conducted to test the hypothesis that the obese heart possesses a decreased
expression of voltage-gated potassium channels, leading to the resulting long QT in ECG
measurements (65). Obese humans display impaired repolarization in cardiomyocytes due to
the prolonging of the QT interval. There is also a known significant association between
obesity and atrial fibrillation and arrhythmias. Sudden cardiac death increase in obese
patients is usually due to arrhythmias (65). Similar observations regarding the
electrophysiology of the obese heart have been made using a diet-induced obesity model in
mice. Diet-induced obesity is the superior model in transgenic mice to induce obesity
because overexpression of a single gene in a mouse may not result in the same
pathophysiology provided by a diet-induced obesity model. The study used the diet-induced
obesity model to investigate the electrophysiological conditions present in obese mice (65).
This study concluded that protein kinase D is activated in obese hearts, leading to a
reduction of cyclic AMP response element binding protein (CREB). This leads to a
decreased expression of potassium channels, thus resulting in long QT and pro-arrhythmic
electrophysiological remodeling in the obese heart. Diet-induced obesity mice showed
similar ECG characteristics to humans, experiencing a significant increase in QT interval
and ventricular ectopy when compared to non-obese controls (65). However, obese people
show more atrial fibrillation than diet-induced obesity mice that exhibit signs of ventricular
arrhythmias.
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Obesity in humans is also associated with an increased risk of developing atrial fibrillation
(AF) (48). Several co-morbidities, such as hypertension, coronary artery disease, congestive
heart failure, and obstructive sleep apnea are shared between obesity and AF (48). The
increase of AF risk in obese patients is associated with a transformation of the atrial
electrophysiology that can be observed in these individuals’ ECG. The study showed P wave
indices (PWI) that were analyzed in obese patients and found that the amount of pericardial
fat was correlated to P-wave duration and P-wave terminal force, and that also PR interval
and P-wave amplitude was significantly associated with increasing BMI (48). The effects of
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obesity on cardiovascular health in mice and humans are evident in the accompanying
changes reflected in ECG.

Translational, genetic obesity and surgical animal models to test heart
function
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To understand the mechanisms of cardiac remodeling in the context of obesity several
animal models have been studied. These models are closely associated with the overweight
or obesity in humans and with coincident morbidities such as impaired glucose tolerance,
insulin resistance, diabetes, and hypertension. To evaluate tissue pathology in a timedependent manner, rodents have been the choice of model to perform studies. Rodent
models are classified into two main categories: transgenic mice with targeted mutations or
diet-induced obesity mice achieved by feeding the animals on the high-fat diet. Furthermore,
these two rodent models are used with minimum invasive surgery to study heart failure
following MI. Most laboratory models of obesity are small inbreed rodents (rats or mice)
and are maintained in small enclosures with a particular diet meant to develop obesity. The
choice of model for a particular experiment depends upon the goal of the study, time and
cost; therefore, young animals are preferred. To evaluate exact mechanism, transgenic
models or models with spontaneous mutations may be used for specific mechanism or for
validation of therapeutic target to determine whether it engages a specific target or pathway
in vivo. In 1959, a spontaneous mutation leading to the markedly obese phenotype in the
Lepob/Lepob mouse was first recognized (84). The characterization and discovery of the
“ob” gene product, leptin in 1994 intensified the motivation to perform research on obesity
genetics (125). To this day, the “ob” gene is one of the most-studied genes of obesity
research. The production of bioactive leptin is prevented by a single-base, spontaneous
mutation of the “ob” gene. Leptin is synthesized predominantly in white adipocytes, and its
secretion is directly proportional to the amount of stored triglyceride. Phenotypically,
hyperphagia, reduced energy expenditure, and hypothermia are distinct features of early
obesity due to lack of leptin (42). Hypercorticosteronemia, insulin resistance associated with
hyperglycemia and hyperinsulinemia, hypothyroidism and growth hormone deficiency are
further defects which lead to the decrease in linear growth. A drawback of this model is that
Lepob/Lepob mice are infertile. Lepob/Lepob mice develop obesity that can be treated
effectively by the administration of exogenous leptin since leptin levels are found to be
highly elevated in MI (82). This model of overweight and obesity is extensively used to
study obesity-induced MI. The leptin receptor-deficient “db/db” mouse, also called the
Leprdb/Lepdb mouse, is phenotypically similar to the Lepob/Lepob mouse (118). These mice
are so-named because there is more marked hyperglycemia on some background strains.
Lepdb/Lepdb mice are also characterized by hyperphagia and reduced energy expenditure,
leading to marked early-onset of obesity. Also, these mice are hypothermic, have decreased
linear growth due to growth hormone deficiency, and are infertile (24) (25). The significant
difference from the Lep ob/Lepob mouse are resistance to leptin due to spontaneous mutation
in leptin receptor. These mice also suffer from morbid obesity, but their leptin levels are
markedly elevated. The db/db mouse has an increased susceptibility to myocardial ischemiareperfusion injury (69) (76). The increased severity of MI in the db/db mouse makes it an
excellent model to investigate heart failure in the setting of obesity-induced diabetes.
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The genetically engineered animal model of leptin receptor deficiency is more accurate and
is known as s/s (disruption of the LRb/STAT3 signal mouse) (14) (13). This mouse carries a
mutation that specifically disrupts the transcription factor STAT3, which is an essential
component of the leptin signaling pathway of the long form of the leptin receptor and
mediates leptin’s effects on energy homeostasis. The homozygous (s/s) mice are
hyperphagic, obese, and fertile. They have normal body length and are less hyperglycemic
compared to the Lepdb/Lepdb mouse. These mice develop severe insulin resistance similar to
that in Lepdb/Lepdb mice, particularly in the liver. These mouse models are essential in
studying STAT3-associated myocardium dysfunctions in obese models (12). The
extracellular domain of the leptin receptor is mutated in the obese Zucker (fa/fa or ‘fatty’ rat)
and the Koletsky rat. Zucker and Kolesky rats show a similar phenotype of hyperphagia and
reduced energy expenditure, leading to morbid obesity (20) with an impaired glucose
tolerance- a growth deficit possibly related to a lower activity of the GH/IGF-1 axis and
hypothyroidis. Koletsky rats have a nonsense and null mutation that leads to undetectable
levels of leptin receptor mRNA expression and lowered fertility (24) (26) (27). The Zucker
fatty rats have a fa/fa mutation associated with a processing defect of the leptin receptor,
which is generated but retained intracellularly. This leads to reduced numbers of leptin
receptors on the cell surface of adipocytes and is associated with decreased leptin binding
and signal transduction. When homozygous for a gene (fa/fa), the Zucker rat is obese,
moderately insulin resistant, and hypertriglyceridemic, but with no progression in diabetes
or cardiovascular complications (6). Thus, these mice are not suitable to study obesitymediated myocardial dysfunction. Zucker Diabetic Fatty (ZDF) rats are the sub strain of
obese Zucker fatty rats displaying early dysregulation of glucose metabolism. ZDF rats fed
on high-fat diet develop early diabetes and altered expression of the glucose transporter
GLUT4 in skeletal muscle (127). These mice show evident vascular dysfunction in the aorta,
coronary arteries, and mesenteric arteries in adult to middle-aged obese ZDF rats with
diabetes (91). The ZDF model has proven to be a useful tool in demonstrating the efficacy of
pharmaceutical agents directed at myocardial injury and lipidemia (124) (120). This similar
rat model is a cross of Zucker (fa/fa) rats with Wistar-Kyoto (WKY) rats. These rats develop
obesity and co-morbidities like insulin resistance, hyperinsulinemia, and hyperlipidemia
similar to the Zucker (fa/fa) rat. Male Wistar-Kyoto fatty rats develop early hyperglycemia
and glucosuria along with insulin resistance (44). These mice have been used to study how
the progression of heart failure following coronary artery ligation surgery is accelerated by
Type 2 diabetes (21). The PPAR-γ knockout mouse model is tissue-specific (adipose), as the
global knockout is embryonically lethal. Ablation or impaired function of PPAR-γ,
specifically in adipose tissue, results in an insulin-resistant lipodystrophic phenotype (119).
These hypomorphic and the ATKO (adipose tissue-specific knockout mice) displayed
average whole body insulin sensitivity when fed a chow diet, and they had hepatic insulin
ATKO, where adipose tissue is unable to store lipids and suppress lipolysis appropriately.
Thus, when challenged with high-fat feeding, it leads to persistently elevated serum lipid and
lipotoxic infiltration of the liver (59). Subsequently, this mouse model develops whole body
insulin resistance due to the impaired suppression of gluconeogenesis as a result of the
lipotoxic insult (50). The PPAR models reveal greater increases than other models in
information regarding the mechanisms of various nuclear transcription factors involved in
the cardiovascular system. Since global deletion of PPAR is embryo-lethal, the use of
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conditional knockout mice (e.g., ECs, VSMCs, macrophages) has been critical to
understanding the mechanism of cardiovascular disease. Coronary artery ligation-induced
progressive heart failure is the first model applied in dogs that mimic ischemic
cardiomyopathy (62). The procedure involves the ligation of the proximal left anterior
descending coronary artery (LAD) accompanied by an intubation and left thoracotomy to
induce MI. This procedure has a higher mortality rate, nearly 50%, due to malign ventricular
tachycardias in the acute phase. TAC in the mouse is an experimental model for pressure
overload-induced cardiac hypertrophy and heart failure (100). These mice models initially
lead to compensated hypertrophy of the heart, which often is associated with a temporary
enhancement of cardiac contractility. With due course of time, however, the response to the
chronic hemodynamic overload becomes maladaptive, resulting in cardiac dilatation and
heart failure. Rockman et al. validated the first murine TAC model (100). This model has
been used as a valuable tool to mimic human hypertensive cardiovascular diseases, and
furthermore, to elucidate fundamental signaling processes involved in the cardiac
hypertrophic response and heart failure development.

Post-MI remodeling in obesity

Author Manuscript
Author Manuscript

Global epidemic obesity is associated with moderate to chronic inflammation. Long
standing obesity may result in cardiac changes, such as left ventricular (LV) hypertrophy,
left atrial (LA) enlargement, and subclinical impairment of LV systolic and diastolic
function. The inflammatory cascade has a critical role in response to cardiac injury, the
involvement of inflammatory mediators in repair, and the remodeling of the infarcted left
ventricle. The pathogenesis of heart failure post-MI is intricately linked with the
development of post-infarction ventricular remodeling (47). Thus, chronic obesity is linked
to an increased risk of dysfunction for the heart, and it is assumed that long-term existence
of obesity will eventually lead to heart failure (5) (22) (122). In the Framingham Heart Study
(73), the population was stratified by BMI and then followed for incident HF that was
diagnosed by adjudicated clinical criteria. The study reported that increased BMI was
associated with an increased risk of heart failure in both men and women, and the risk was
graded across categories of increasing BMI. Though it has been well accepted that obesity
increases the risk of developing heart disease, recent reports documented a statistically
significant survival benefit in obese patients once they were diagnosed with heart diseases
(57) (63) (79) (85) (38). The recent report from our group has shown the improved cardiac
function in obese mice models (60). The study shed light on post-MI remodeling in obese
and diabetic KKAY mice that showed an attenuated inflammatory response. The decrease in
the inflammatory response included reduced macrophage density in the infarcted area with
reduced collagen I and III levels and reduced neovascularization in the infarcted area of
KKAy mice. The study concluded that diabetes worsened post-MI survival but attenuated LV
remodeling in surviving mice, with improved cardiac function in post-MI settings. In
another study, obese and hyperphagic mice showed improved post-MI survival with
attenuated LV remodeling. This was a result of modifying the leukocyte infiltration kinetics,
as well as the angiogenic response in absence brain-derived neurotrophic factor (BDNF) in
heterozygous mice (54). Both these studies align with the obesity paradox that obesity may
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both elicit cardiac disease as well as protect from cardiovascular death. This now requires
further mechanistic analyses at the cellular, molecular, systematic and integrative levels.

Saturated fat vs. polyunsaturated fat
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Author Manuscript

The amount and source of dietary fat intake in the human diet can have significant
implications on cardiovascular health. In recent years, there has been a shift in Western diets
due to the increased use of plant oils over animal fats in cooking and consumption of
processed food (87). This change has led to an increased intake of saturated fatty acids
(SFA) and polyunsaturated fatty acids (PUFA), in particular the n-6 PUFA, linoleic acid
(LA) (16). LA is particularly of cardiovascular interest because it has that elongate to long
chain derivative, arachidonic acid (AA) leads to the production of pro-inflammatory
compounds. LA is a competitor of the short-chain n-3 PUFA alpha-linoleic acid (ALA) for
enzymes required to convert to their long chain derivatives, eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA), subsequent entry to the plasma membrane. Both SFA and n-3
dietary fatty acids are involved in forming proinflammatory and immunoresolvent mediators
(Figure 4; reviewed elsewhere (71)), indicating that diets high in LA may decrease the
utilization of the cardioprotective benefits derived from intake of n-3 PUFA. This
competition from LA suggests that limiting the intake of LA will result in a reduction of n-6
derived pro-inflammatory mediators, while also enhancing the efficacy of long-chain n-3
PUFA. A recent study was able to show that a diet consisting of low LA taken for four
weeks can reduce total LA and total n-6 PUFA content of plasma phospholipids, while also
increasing n-3 long-chain PUFA without increasing their consumption due to their improved
incorporation (123). It is thought that replacing SFA with PUFA in the diet will result in
cardioprotective effects, but it is clear that the amount and type of PUFA in the diet will
cause differential effects based on their content (7). A case-control study from Italy
examined the FA composition of whole blood in patients with a recent MI and compared
with matched controls, finding that PUFA of both n-3 and n-6 series are significantly lower
in patients with MI (81). It was also found that MI patients had higher levels of SFA and
monounsaturated fatty acids. Another review article on dietary fats in relation to
cardiovascular health found evidence that n-6 PUFA promotes inflammation and exacerbates
many diseased states while n-3 PUFA works to counter these effects (75). This review
refutes earlier evidence that SFA intake increased coronary risk and put forth that
replacement of SFA in the diet with carbohydrates, sugar, in particular, has driven an
increase in obesity and its corresponding adverse health effects. Many other studies have
corroborated the beneficial effects of n-3 PUFA intake on cardiovascular health and
outcomes (31) (11) (43) (30) (34) and its ability to reduce atrial fibrillation (58) (72) (121).
In summary, current literature shows diversified effects of fat to cardiovascular health.
Higher levels of n-3 PUFA in the blood are affected by n-6 PUFA intake. The replacement of
SFA with PUFA provides cardioprotective benefits (103) due to the action of n-3 long chain
derivatives EPA and DHA. Further research should focus on providing answers on the ideal
amounts of n-6 to n-3 PUFA to provide cardiovascular protection and of the extent to which
the dietary amounts of EPA and DHA, either individually or synergistically, affect
cardiovascular health.
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Diet intake and lipotoxicity
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Dietary lipids modulate cardiac function via membrane phospholipids, either as signaling
molecules or ligands for nuclear receptors, are predominant substrate for cardiac
mitochondria to generate energy through oxidative phosphorylation (105). The peroxisome
proliferator–activated receptors (PPARs-α, β, and δ) are one of the first genetic targets for
fat. PPARs are members of the nuclear receptors family and can be activated by both dietary
fatty acid as well as their metabolic derivatives in the body, and they serve as lipid sensors
for myocardial energy metabolism (Figure 5) (41). An abnormality in myocardial energy
metabolism, specifically an overall misbalance of mitochondrial oxidative catabolism and
anaerobic glycolytic pathways (45) (10) (114), is the primary factor for the myocardium
dysfunction and failing heart. These metabolic changes are mediated partially by decreased
expression of genes encoding enzymes involved in mitochondrial FAO (fatty acid oxidation)
and oxidative phosphorylation pathways secondary to deactivation of the PPAR/PGC-1α
axis (45) (9). PPARα deactivation is observed in human heart failure patients (10) (98).
PPAR/PGC-1α axis plays an important role in the failing heart indirectly through dietary
intake.

Impact of Mediterranean and DASH diets on preventing cardiovascular
disease

Author Manuscript

The quality and quantity of the fat intake and other macro or micro nutrients clearly have an
effect on cardiovascular health and has led to the development of specific diets aimed at
improving cardiovascular health. Two of the most studied diets designed to improve
cardiovascular health are the Mediterranean diet and Dietary Approaches to Stop
Hypertension (DASH) diet (116).

Author Manuscript

The Mediterranean diet originated in Crete and Italy; it consists of a high fat intake- 40–50%
of daily calories with SFA composing ~8% and monounsaturated fatty acids (MUFA) at 15–
25% total calories (39). The diet also consists high fish and plant intake, leading to high n-3
PUFA levels and a much lower ratio of n-6 to n-3 PUFA as compared to other diets. The
foods consumed in this diet include fresh fruits/vegetables, whole bread/grains, legumes,
nuts, olive oil, moderate dairy products, eggs, fish, and chicken (97). The diet discourages
the consumption of red meat and allows reasonable quantities of wine to be taken with
meals. The Mediterranean diet (MedDiet) is extensively studied for its effects on CVD
incidence and development. One randomized trial, which enrolled 7447 participants at high
risk for CVD, tested the effects of two variations of the Mediterranean diet against a control
diet on cardiovascular outcomes (40). The results showed that both variations of this diet
were associated with a reduction in the incidence of many cardiovascular events. Extensive
reports on the subject of the Mediterranean diet found that its intervention is associated with
a 38% relative reduction in the risk of CVD clinical events (83). The beneficial
cardiovascular effects gained from this diet rise from its ability to cause improved LV
function and blood pressure. One group sought to test how LV function changed in response
to adherence to the MedDiet by tracking 372 heart failure patients’ LV function and dietary
habits (23). The results showed that patients who more closely followed the MedDiet
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experienced improved LV fill pressure and systolic function of both ventricles. The antiinflammatory properties inferred from the diet are thought to drive the impact of diastolic
filling pressures. Another collection of reports, which included randomized controlled trials
where the MedDiet was used as the intervention in adults at high risk of CVD and healthy
adults, found that the diet lowered blood pressure in 3 of 5 trials reporting that outcome (97).
The utilization of the MedDiet has been positively associated with improved LV function
and blood pressures.
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Like the MedDiet, the DASH diet has also been shown to have positive effects on
cardiovascular outcomes (Figure 6). The DASH diet was a nutritional program begun in the
1990’s that was aimed to reduce hypertension with the hopes that this results in a reduction
of CVD events. The main components of the diet are vegetables, fruit, low-fat dairy
products, whole grains, chicken, fish and nuts. The diet is low in fat, meat, sweets, and soda.
A correctly followed DASH diet will provide more calcium, magnesium, potassium, and
dietary fiber, while also providing less fat, SFA, cholesterol, and sodium compared to an
average Western diet (39). There have been several studies aimed at evaluating the DASH
diet’s ability to reduce blood pressure/hypertension and improved CVD outcome. In one
study, obese hypertensives were subjected to DASH diet for three weeks in comparison to a
regular diet with added potassium, magnesium, and fiber supplements. The results found
that the DASH diet more efficiently lowered blood pressure and improved endothelial
function (3). Another study focused on the effects of the DASH diet alone and in
conjunction with exercise to see the difference in hypertension relieving capabilities (17).
The results showed that exercise along with the DASH diet attenuates the blood pressure
lowering more efficiently than the diet alone. Participants who also exercised showed larger
blood pressure reductions and also more improvements in vascular and autonomic function
along with a reduction in LV mass. Diets that are consistent with the DASH guidelines are
also associated with a lower incidence of heart failure (77). The more specific effects of the
DASH diet on LV function were elucidated through examining the effect of the DASH diet
on patients that had heart failure with preserved ejection fraction (66). These patients that
were treated with a sodium-restricted DASH diet showed improvements in ventricular
diastolic function, arterial elastance, and ventricular-arterial coupling. A meta-analysis of
DASH diet studies found that the diet can significantly protect against CVD, coronary heart
disease, stroke and heart failure by 20%, 21%, 19%, and 29%, respectively (102). Similar
results of the DASH diet were found in a Chinese population study, showing that adherence
to the DASH diet has clear benefits in managing long-term blood pressure and reducing the
risk of stroke (78). It is evident that adherence to the DASH diet will be effective in lowering
blood pressure and the cardiovascular benefits that go along with improving hypertension
(78).
The MedDiet and DASH diet both have obvious benefits for cardiovascular outcomes. The
MedDiet operates more through its ability to establish healthy n-3 intake and n-6/n-3 PUFA
ratios to improve cardiovascular outcome, while the DASH diet aims specifically at lowering
blood pressure to improve cardiovascular health (Table 1). Both diets show positive effects
on cardiac health development, and their mechanisms of action could provide insight into
new ways of improving cardiovascular health.
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Differential cardiac health outcome in obesity
By and large, numerous rodent models of diet have been used for studying cardiac
pathophysiology and the clinical aspects of diet in heart failure. These studies account for
the paradox due to: 1) variation in the fat percentage and its source; 2) age of the animals
used in the studies (most likely young rodents are widely used); 3) gender specificity (the
selection of only male or female); and 4) dose and duration of diet feeding (short-term vs.
long-term). These four factors widely impact the studies and their outcomes; therefore,
studies involving the diet or fat intake should be critically designed to translate to the clinical
implication of cardiac health.

Future prospective
Author Manuscript

The manipulation of dietary fat quality and quantity shows promise in the prevention and
treatment of heart failure. Additional clinical and animal studies are needed to determine: 1)
the optimal diet, i.e. quality and quantity of fatty acids that are the prime substrates for
lowering the inflammation with an age-dependent approach; 2) evaluate fat-metabolizing
enzyme capacity (genetic machinery) in heart failure pathophysiology; and 3) understanding
the role of fatty acid metabolism and fatty acid-derived metabolites in resolving and nonresolving inflammation in heart failure pathology. Thus, studying these three critical points
will help scientists and the community in fine-tuning the impact of obesity-related
complicated cardiovascular effects on health.

Conclusion
Author Manuscript

Over nutrition or genetic originated obesity is the multifaceted metabolic disorder that has a
long-term dynamic adverse effect on the systemic inflammation and integrative
cardiovascular network. Obesity-induced overactive unresolved inflammation and
dysregulated interaction of fatty acids with lipid processing enzymes aggravate heart failure
pathology. Thus, obesity-mediated cardiac pathology is originated from diverse metabolic
factors that coordinate the systemically inflamed milieu to drive cardiovascular dysfunction,
particularly in obesity. Cardiac dysfunction-related mechanisms integrate with the splenic
and renal network to contribute the progressive non-resolving milieu. Therefore, reduction
of risk factors with comprehensive integrative approach will be a suitable strategy to reduce
cardiovascular burden. Detailed mechanistic studies of obesity-mediated overactive
inflammation in cardiovascular pathobiology are warranted to identify the novel targets and
treatment strategy consequently to improve cardiac health.
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Obesity and related metabolic dysregulation set the platform for a vicious pro-inflammatory
environment for post-MI pathology with marked dysregulation of the cardiosplenic and
cardiorenal network in heart failure pathology. Bone marrow adiposity, particularly in obese,
diabetes and aging populations, supplies pro-inflammatory monocytes and enhances the
atherosclerotic conditions that simulate an MI event, as well as subsequent renal and
pulmonary edema and chronic inflammation heart failure pathology. Increased macrophage
(DAPI/F480/CD169-red) density in aging mice kidney (18 months) compared with young
mice (2 months old) shows chronic glomeruli inflammation.
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Obesity superimposed on aging magnify non-resolving inflammation. Post-MI acute
inflammation triggers changes in the kinetics and leukocytes quantity from acute phase (d1–
d3), resolution phase (d3–d7) and fibrotic/chronic phase (d5–d28). This results in imbalance
in generation of resolving and non-resolving lipid in the acute and resolving phases of
myocardium healing thereby impaired resolution of inflammation. Levels of resolving and
pro-inflammatory lipid mediators determine the resolving capacity of myocardium healing
in heart failure pathology.
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Multiple mediators generated in the spleen, adipose tissue, liver and bone marrow
contributes to myocardial healing. Adipokines (liver adiposity), bone marrow, and spleen
collectively coordinate low-grade inflammation in heart failure. The low-grade inflammation
is sustained during myocardial healing leading to impaired resolution of inflammation in
obesity.
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Figure 4.

Diversity of lipid mediators derived from polyunsaturated n-6 fatty acids and
immunoresolvents derived from n-3 fatty acid. Dietary sources of n-3 and n-6 fatty acids and
their respective lipid metabolites are illustrated to define the differential chemical milieu
responsive to dietary factors.
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Figure 5.

Fatty acid metabolism gene network and impaired fatty acid oxidation. Fatty acid intake
alters the oxidative metabolism via direct and indirect interaction with the metabolic gene
network that generates energy in homeostasis. The imbalance or over and or under activation
of metabolic genes leads to lipotoxicity and heart failure.
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Figure 6.

Impact of salt and fat enriched diet in obesity, diabetes and hypertension leading to MI and
heart failure events. Solid lines indicate direct contribution to pathology, and dotted lines
indicate indirect effect. Mediterranean and DASH (dietary approaches to stop hypertension)
diets show capacity of reducing the overall rate of cardiovascular disease and heart failure
events.
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Summarized features of DASH and Mediterranean diet that showed evidence to reduce cardiovascular events
in epidemiological studies. Both diets have many common features.
Diet features

Mediterranean diet

DASH diet

Fruit

↑ Fruit

↑ Fruit

Vegetables

↑ Vegetables

↑ Vegetables

Dairy products

Moderate amounts of low-fat dairy

moderate amounts of alcohol and dairy products

Protein

↑ Legumes and nuts
↓ Animal protein

↑ Whole grain and
↓ red or processed meats

Fish

↑ Fish

↑ Fish

Sodium

-

↓

Sweet

↓

↓
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DASH: This diet primarily designed to reduce blood pressure.
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